In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript ... presentation offering our vaccine in a prefilled syringe ...

and that they underestimated providers' preference for single-dose vials, which they didn't offer. Between the lines: Unlike ...

Novavax said on Tuesday that it has entered into a termination and settlement agreement with the UK Health Security Agency ...

Dr. Marty discusses why the FDA put a hold on the Novavax COVID-Flu vaccines and how their COVID vaccine is different from the others that are offered. She also explains the possible connections ...

Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...

Graeme Sloan / Bloomberg via Getty Images The Food and Drug Administration put clinical holds on Novavax's COVID-19 and flu combination vaccine and its standalone flu shot because of safety concerns.

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA approves new vaccine, and revenue guidance is lowered. Vandana Singh FDA Gives ...

Novavax, Inc. ( NASDAQ: NVAX) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET ...

In early pandemic days, Novavax (NASDAQ: NVAX) shares soared as investors bet on the company's ability to bring a coronavirus vaccine to market. But as the biotech fell behind in the race and ...